Skip to main content

Strides Shasun receives USFDA nod for Ranitidine Tablets

 

Clinical courses

Strides Shasun Limited  announced that it has received approval from the United States Food & Drug Administration (USFDA) for Ranitidine Tablets USP, 150 mg and 300 mg.

Ranitidine tablet is the first integrated product approval where the API and formulationswill be manufactured at erstwhile Shasun Pharmaceutical’s Cuddalore and Pondicherry
facilities respectively.

According to IMS data (MAT June 2016), the US market for Ranitidine Tablets USP, 150 mg and 300 mg. is approximately USD 125 Million. The product to be launched immediately will be marketed by Strides Pharma Inc in the US Market

<< Pharma News

Subscribe to PharmaTutor News Alerts by Email